ScholarLens Back to search
2009•Acta Academiae Medicinae WeifangRequires access

The Efficacy and Safety of Recombinant Human Tumor Necrosis Factor-α Receptor II for Treatment of Rheumatoid Arthritis

Ming Zhang

Open publisher page 0 citations

Abstract

Objective To study the efficacy and safety of Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ(Etanercept) on the activity of rheumatoid arthritis (RA).Methods Sixty-eight patients with active RA were randomly divided into two groups.Experimental group:25mg Ecep was given twice times perweek by subcutaneous injection;The control group:1.0 sulfasalazine (SASP) for twice a day and 10mg methotrexate (MTX) for once a week was given by oral administration.The course of treatment persisted 24 weeks.Results Two,four,eight,twelve and twenty-four weeks after treatment,the ACR50 effective rate in Ecep group was higher than that of SASP+MTX group.The difference between the two groups was significant (P0.05);The difference between the two groups in incidence of adverse reactions was not significant (P0.05).Conclusion Etanercept has good efficacy and safety for the treatment of active RA.

About this research paper

What this paper is about

Objective To study the efficacy and safety of Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ(Etanercept) on the activity of rheumatoid arthritis (RA).Methods Sixty-eight patients with active RA were randomly divided into two groups.Experimental group:25mg Ecep was given twice times perweek by subcutaneous injection;The control group:1.0 sulfasalazine (SASP) for twice a day and 10mg methotrexate (MTX) for once a week was given by oral administration.The course of treatment persisted 24 weeks.Results Two,four,eight,twelve and twenty-four weeks after treatment,the ACR50 effective rate in Ecep group was higher than that of SASP+MTX group.The difference between the two groups was significant (P0.05);The difference between the two groups in incidence of adverse reactions was not significant (P0.05).Conclusion Etanercept has good efficacy and safety for the treatment of active RA.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Objective To study the efficacy and safety of Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ(Etanercept) on the activity of rheumatoid arthritis (RA).Methods Sixty-eight patients with active RA were randomly divided into two groups.Experimental group:25mg Ecep was given twice times perweek by subcutaneous injection;The control group:1.0 sulfasalazine (SASP) for twice a day and 10mg methotrexate (MTX) for once a week was given by oral administration.The course of treatment persisted 24 weeks.Results Two,four,eight,twelve and twenty-four weeks after treatment,the ACR50 effective rate in Ecep group was higher than that of SASP+MTX group.The difference between the two groups was significant (P0.05);The difference between the two groups in incidence of adverse reactions was not significant (P0.05).Conclusion Etanercept has good efficacy and safety for the treatment of active RA.

Key concepts: Medicine, Etanercept, Rheumatoid arthritis, Sulfasalazine, Methotrexate, Tumor necrosis factor alpha, Adverse effect, Incidence (geometry)

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
The Efficacy and Safety of Recombinant Human Tumor Necrosis Factor-α Receptor II for Treatment of Rheumatoid Arthritis — Research Paper | ScholarLens